Drug Facts and Comparisons News. MedImmune Inc. press release. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.
Outbreaks are seasonal and are most common during the fall and winter months.
Ribavirin is recommended for continuous aerosol administration via an oxygen hood, tent or mask for 12 to 20 hours daily for a mean of 4 days. Special precautions are essential in mechanically ventilated patients to prevent complications and reduce the risk of crystalline precipitation in the circuit along with subsequent ventilator dysfunction. Teratogenic toxicities have been observed in animal models. These effects have not been reported in humans. Respigam was released in early 1996.